arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Aclarion, Inc.

ACON
$2.95 ▲ +0.33 (+12.38%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
23 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Aclarion, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.3M
Dividend Yield —
Revenue Growth 30.5% ↗
Op. Margin —
ROIC -17.1% ↘
FCF / Share $-1.08 ↗
Trailing P/E —
Price / Book 0.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$25.21K
↑ +30.5% —
Net Income Profit after all expenses
$-2.85M
↓ -40.1% —
FCF / Share Free cash flow per share
$-1.08
↑ +13.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 6 years · 23 quarters